Keyphrases
Melanoma
72%
Metastatic Melanoma
58%
Ipilimumab
52%
Advanced Melanoma
43%
Pembrolizumab
39%
Merkel Cell Carcinoma
36%
Tumor
27%
Tremelimumab
22%
Phase II Trial
21%
Programmed Death-ligand 1 (PD-L1)
19%
Checkpoint Inhibitors
19%
Targeted Therapy
18%
Progression-free Survival
18%
Phase II Study
17%
RNA Transcripts
16%
Stage III Melanoma
15%
Systemic Therapy
15%
Adverse Events
14%
Advanced Basal Cell Carcinoma
14%
Vismodegib
14%
Temozolomide
14%
Antitumor
14%
NY-ESO-1
14%
Talimogene Laherparepvec (T-VEC)
14%
Whole Blood RNA
14%
Immune Response
14%
Clinical Benefit
14%
Immune Checkpoint Inhibitors
13%
Objective Response Rate
13%
Stage IV Melanoma
13%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
13%
Overall Survival
12%
Clinical Response
12%
Immune-related Adverse Events
12%
Melanoma Patients
11%
Confidence Interval
11%
Nivolumab
11%
CTLA-4 Blockade
11%
Immune Regulation
10%
Gene Signature
10%
Response Rate
10%
Basal Cell Carcinoma
10%
Duration of Response
10%
Melanoma Cells
10%
Cancer Immunotherapy
9%
Trial Network
9%
Immunotherapy Trials
9%
Clinical Trials
9%
Adjuvant Therapy
9%
Virus
9%
Medicine and Dentistry
Melanoma
100%
Pembrolizumab
44%
Metastatic Melanoma
43%
Neoplasm
37%
Merkel Cell Carcinoma
36%
Ipilimumab
31%
Immunotherapy
24%
Immune Checkpoint Inhibitor
18%
Adverse Event
18%
Targeted Therapy
18%
Clinical Trial
17%
Progression Free Survival
16%
Immunity
15%
Temozolomide
14%
Ticilimumab
14%
Side Effect
14%
Disease
13%
Systemic Therapy
13%
Overall Survival
12%
Malignant Neoplasm
11%
Cancer
11%
Immune-Related Adverse Events
11%
CTLA-4
11%
Nivolumab
11%
Phase II Trials
10%
Cancer Cell
9%
Messenger RNA
9%
Metastatic Carcinoma
9%
Cancer Immunotherapy
9%
Melanoma Cell
8%
Health Care Cost
8%
Granulocyte Macrophage Colony Stimulating Factor
8%
Merkel Cell
8%
Tumor Regression
8%
Clinical Study
8%
Programmed Death-Ligand 1
8%
Immune Response
7%
Methotrexate
7%
Carboxymethyl Cellulose
7%
Polylysine
7%
Acute Febrile Neutrophilic Dermatosis
7%
Diphenylcyclopropenone
7%
Skin Carcinoma
7%
Imatinib
7%
Neoadjuvant Therapy
7%
In-Transit Metastasis
7%
Elevated Transaminases
7%
Carboxymethylcellulose Polycytidylic Polyinosinic Acid Polylysine
7%
Bevacizumab
7%
Bispecific Antibody
7%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
74%
Ipilimumab
39%
Neoplasm
33%
Metastatic Melanoma
30%
Pembrolizumab
29%
Progression Free Survival
22%
Merkel Cell Carcinoma
22%
Tremelimumab
22%
Malignant Neoplasm
16%
Immunotherapy
15%
Adverse Event
15%
Cytotoxic T Lymphocyte Antigen 4
14%
Temozolomide
14%
Vismodegib
14%
Basal Cell Carcinoma
14%
Talimogene Laherparepvec
14%
Chemotherapy
14%
Clinical Trial
13%
Disease
13%
Overall Survival
11%
Messenger RNA
10%
Phase II Trials
10%
Carboxymethylcellulose Polycytidylic Polyinosinic Acid Polylysine
8%
Tumor Regression
8%
Clinical Study
8%
Diarrhea
7%
Gemcitabine
7%
Cytotoxic T Lymphocyte Antigen 4 Antibody
7%
Thyrotropin
7%
Diphencyprone
7%
Skin Carcinoma
7%
Veliparib
7%
Chaperone
7%
Hypertransaminasemia
7%
Heat Shock Protein 90 Inhibitor
7%
In-Transit Metastasis
7%
Bevacizumab
7%
Elesclomol
7%
Polylysine
7%
Paclitaxel
7%
Carboxymethylcellulose
7%
Critical Micelle Concentration
7%
Inflammation
6%
Thyroid Disease
6%